Determination of Alteration in Micromeritic Properties of a Solid Dispersion: Brunauer-Emmett-Teller Based Adsorption

Lovepreet Singh1, Lakhvir Kaur2, Gurjeet Singh1

  • 1Department of Pharmaceutics, Khalsa College of Pharmacy, Amritsar, Punjab, 143001, India.

AAPS Pharmscitech
|July 28, 2022
PubMed

Insights

This study enhances bexarotene solubility using solid dispersion technology with green locust bean gum. Optimized formulations show improved particle size, solubility, and surface area for cancer and potential COVID-19 treatments.

Area of Science:

  • Pharmaceutical Technology
  • Materials Science

Background:

  • Bexarotene is an anti-cancer drug with poor solubility, limiting its efficacy.
  • Bexarotene exhibits potential inhibitory action against COVID-19 targets (main protease and ACE2 receptors).
  • Solid dispersion technology offers a promising approach to overcome poor drug solubility.

Purpose of the Study:

  • To enhance the solubility and dissolution rate of bexarotene using solid dispersion.
  • To compare the efficacy of green locust bean gum (MLBG) and poloxamer as polymers for bexarotene solid dispersions.
  • To investigate the mechanism of solubility enhancement and optimize drug-to-polymer ratios.

Main Methods:

  • Preparation of bexarotene solid dispersions using lyophilization with MLBG and poloxamer.
  • Characterization using XRD, TGA, SEM, DSC, particle size analysis, BET, and Langmuir surface area analysis.
  • Evaluation of solubility, dissolution rate, porosity, and specific surface area.

Main Results:

  • Optimized solid dispersion with MLBG showed significantly reduced particle size (745.7±4.4 nm) and enhanced solubility (63.97%).
  • MLBG-based dispersion exhibited improved pore size (211.597 Å) and surface area (BET: 5.6413 m²/g, Langmuir: 8.2757 m²/g).
  • BET analysis elucidated the impact of polymer concentration on dispersion characteristics.

Conclusions:

  • Green locust bean gum is an effective polymer for creating porous bexarotene solid dispersions with enhanced solubility.
  • Solid dispersion technology, particularly with MLBG, offers a viable strategy to improve bexarotene's pharmaceutical profile.
  • The findings support further development of bexarotene solid dispersions for therapeutic applications, including potential antiviral uses.